Get the Stockscreener App
3.07
2.85%
-0.09
Exagen Inc stock is traded at $3.07, with a volume of 154.70K.
It is down -2.85% in the last 24 hours and down -6.40% over the past month.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
See More
Previous Close:
$3.16
Open:
$3.16
24h Volume:
154.70K
Relative Volume:
0.34
Market Cap:
$69.58M
Revenue:
$66.58M
Net Income/Loss:
$-19.95M
P/E Ratio:
-3.3377
EPS:
-0.9198
Net Cash Flow:
$-14.27M
1W Performance:
-6.69%
1M Performance:
-6.40%
6M Performance:
-68.48%
1Y Performance:
-8.36%
1-Day Range:
$3.02
$3.20
1-Week Range:
$2.91
$3.787
52-Week Range:
$2.91
$12.23
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
3.07 | 69.58M | 66.58M | -19.95M | -14.27M | -0.9198 |
|
TMO
Thermo Fisher Scientific Inc
|
464.37 | 172.51B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.32 | 132.46B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
573.82 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.51 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
286.57 | 28.11B | 3.17B | 642.63M | 516.49M | 10.77 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | B. Riley Securities | Buy |
| Jul-30-25 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-23-25 | Initiated | Craig Hallum | Buy |
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat and Cautious 2026 Outl - AD HOC NEWS
Exagen stock price target lowered to $10 by Canaccord on margin outlook - Investing.com UK
KeyBanc cuts Exagen stock price target on pricing headwinds - Investing.com Nigeria
Exagen (XGN): Canaccord Genuity Lowers Price Target to $10.00 | - GuruFocus
Canaccord Genuity Group Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat
Exagen Inc. 2025 Annual Report: Innovative AVISE® Autoimmune Disease Testing, Business Strategy, Pipeline, and Intellectual Property Overview - Minichart
Analyst John Wilkin Lowers Price Target for Exagen (XGN) | XGN S - GuruFocus
KeyBanc cuts Exagen stock price target on pricing headwinds By Investing.com - Investing.com India
Exagen (NASDAQ:XGN) Price Target Cut to $10.00 by Analysts at Craig Hallum - MarketBeat
XGN: Keybanc Lowers Price Target to $10, Maintains Overweight Ra - GuruFocus
KeyCorp Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat
Exagen Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-03-11 - Seeking Alpha
Exagen stock price target lowered to $10 by Canaccord on margin outlook By Investing.com - Investing.com Canada
Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence - MSN
BTIG cuts Exagen stock price target to $9 on lower revenue outlook By Investing.com - Investing.com India
William Blair Maintains Outperform on Exagen Inc. (XGN) March 2026 - Meyka
BTIG cuts Exagen stock price target to $9 on lower revenue outlook - Investing.com India
Exagen (XGN) Rating Maintained by BTIG, Price Target Lowered to $9.00 | XGN Stock News - GuruFocus
Exagen (NASDAQ:XGN) Price Target Lowered to $9.00 at BTIG Research - MarketBeat
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments By GuruFocus - Investing.com Canada
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments - GuruFocus
4 Analysts Have This To Say About Exagen - Benzinga
Exagen stock maintains Outperform rating at William Blair By Investing.com - Investing.com India
Exagen stock maintains Outperform rating at William Blair - Investing.com Australia
Exagen Q4 2025 Earnings Call Transcript - MarketBeat
Exagen Inc. Reports Strong Q4 and Full-Year 2025 Financial Results – Earnings Press Release March 2026 - Minichart
Exagen Q4 Earnings Call Highlights - Yahoo Finance
Exagen (XGN) Achieves Record Q4 Revenue, Driven by Test Volume G - GuruFocus
XGN Forecasts Significant Revenue Growth by 2026 - GuruFocus
Earnings call transcript: Exagen Inc. misses Q4 2025 earnings expectations - Investing.com Nigeria
Exagen 2025 10-K: Revenue $66.6M; net loss $(19.95)M - TradingView
XGN: Record 2025 revenue of $66.6M (+19.7%) with net loss of $20.0M; strong AVISE® CTD growth - TradingView
Exagen Inc. (NASDAQ:XGN) Reports Record 2025 Revenue and Provides 2026 Outlook - ChartMill
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Exagen (NASDAQ:XGN) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
EXAGEN DIAGNOSTICS ($XGN) Releases Q4 2025 Earnings - Quiver Quantitative
Exagen reports record 2025 revenue $66.6M, ASP rises to $441; Q4 revenue $16.6M - TradingView
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results - The Manila Times
Exagen Earnings Report: Q4 Overview - Benzinga
BRIEF-Exagen Inc. Q4 Revenue USD 16.631 Million Vs. IBES Estimate USD 16.6 Million - TradingView
Autoimmune tests for over 137,000 patients power Exagen's 20% revenue rise - Stock Titan
Exagen Inc. (XGN) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
A Peek at Exagen's Future Earnings - Benzinga
XGN: B. Riley Securities Lowers Price Target, Maintains Buy Rati - GuruFocus
Insider Sell: Can Exagen Inc grow without dilutionJuly 2025 PreEarnings & AI Driven Stock Reports - baoquankhu1.vn
Aug Spikes: How strong is Exagen Inc. stock balance sheetTrade Analysis Summary & AI Enhanced Trade Execution Alerts - Naître et grandir
Exagen announces resale of up to 1.15M shares - MSN
Exagen Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Exagen Inc. (NASDAQ:XGN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Exagen Inc. (NASDAQ:XGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
John Aballi Sells 15,698 Shares of Exagen (NASDAQ:XGN) Stock - MarketBeat
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):